Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.65 |
| ▸ | JAK1 | P23458 | 12/20 | 0.64 |
| ▸ | TYK2 | P29597 | 2/20 | 0.61 |
| ▸ | JAK3 | P52333 | 2/20 | 0.61 |
| ▸ | IKBKB | O14920 | 1/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | SYK | P43405 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL20496652 | 0.95 | JAK2 (0.61) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL2760293 | 0.83 | JAK2 (0.83) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL18405534 | 0.82 | JAK2 (0.84) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13031271 | 0.82 | JAK2 (0.85) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL13031553 | 0.82 | JAK2 (0.76) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL2185993 | 0.79 | JAK2 (0.82) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL2237531 | 0.79 | JAK2 (1.00) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL11916701 | 0.79 | JAK1 (1.00) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL25311264 | 0.79 | TYK2 (0.83) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL2238602 | 0.78 | JAK2 (0.80) | JAK2JAK1TYK2JAK3IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144800-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR | ALFASIGMA S.P.A. (IT) | 2026-05-28 | — | — | US | disclosed |
| US-12502394-B2 | Pharmaceutical compositions comprising a JAK inhibitor | ALFASIGMA S.P.A. (IT) | 2025-12-23 | — | — | US | disclosed |
| US-20240277725-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR | ALFASIGMA S.P.A. (IT) | 2024-08-22 | — | — | US | disclosed |
| EP-4368173-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR | Galapagos N.V. (BE) | 2024-05-15 | — | — | EP | disclosed |
| US-11975008-B2 | Pharmaceutical compositions comprising a JAK inhibitor | GALAPAGOS NV (BE) | 2024-05-07 | — | — | US | disclosed |
| EP-3595667-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR | GALAPAGOS NV (BE) | 2023-12-20 | — | — | EP | disclosed |
| US-20210353634-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR | ALFASIGMA S.P.A. (IT) | 2021-11-18 | — | — | US | disclosed |
| WO-2019040706-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO | ACLARIS THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| US-20180311247-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | GILEAD SCIENCES, INC. | 2018-11-01 | — | — | US | disclosed |
| WO-2018169875-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR | GILEAD SCIENCES, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180263997-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR | GALAPAGOS NV (BE) | 2018-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144800-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR | JAK1, JAK3, FER | JAK2 6/4885JAK1 1/4885TYK2 32/4885 |
| US-20210353634-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885TYK2 7/4885 |
| US-20240277725-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885TYK2 7/4885 |
| US-20180311247-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | BRD4, JAK2, JAK1 | JAK2 2/4885JAK1 3/4885TYK2 42/4885 |
| US-11975008-B2 | Pharmaceutical compositions comprising a JAK inhibitor | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885TYK2 5/4885 |
| US-20180263997-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885TYK2 7/4885 |
| US-12502394-B2 | Pharmaceutical compositions comprising a JAK inhibitor | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885TYK2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.